{"id":"NCT01323621","sponsor":"GlaxoSmithKline","briefTitle":"Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-18","primaryCompletion":"2012-01-01","completion":"2012-01-24","firstPosted":"2011-03-25","resultsPosted":"2014-02-06","lastUpdate":"2018-02-15"},"enrollment":512,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg","otherNames":[]},{"type":"DRUG","name":"Fluticasone Propionate 250mcg / salmeterol 50mcg","otherNames":[]},{"type":"DRUG","name":"Double-dummy placebo","otherNames":[]},{"type":"DRUG","name":"Salbutamol as needed","otherNames":[]}],"arms":[{"label":"Fluticasone Furoate / GW642444 (vilanterol)","type":"EXPERIMENTAL"},{"label":"Fluticasone Propionate / salmeterol","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.","primaryOutcome":{"measure":"Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84","timeFrame":"Baseline (Day 1) and Day 84","effectByArm":[{"arm":"FSC 250/50 µg BID","deltaMin":0.114,"sd":0.0183},{"arm":"FF/VI 100/25 µg QD","deltaMin":0.142,"sd":0.0182}],"pValues":[{"comp":"OG000 vs OG001","p":"0.267"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":51,"countries":["United States","Germany","Italy","South Africa","Spain","Ukraine"]},"refs":{"pmids":["24998880"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":252},"commonTop":["Headache"]}}